A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Completed · Phase 3 · NCT03941964
Conditions: Acute Myeloid Leukemia (AML), Cancer
At a glance
- Research payments reported, 2025
- $875
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- AbbVie
- Tested
- Venetoclax (drug), Azacitidine (drug), Decitabine (drug)
- Dates
- Started 2019-08-15; completion 2022-03-14
- Results posted
- Yes
A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.
From ClinicalTrials.gov, last updated 2023-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $875 in research payments for this study in 2025 (1 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $875
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.